First-half OTC derivatives volumes rise 15%

The growth in OTC derivatives far outstripped that of exchanges during the same period, where open positions grew 1%. This reversed the situation in the second half of last year when OTC contracts grew 11%, compared with a 22% rise in exchange-traded contracts.

Interest rate derivatives, with $90 trillion in outstandings, were again the largest component of the OTC business, with forward rate agreements, interest rate swaps and interest rate options, growing at roughly equal rates.

Interest rate swaps notionals hit $68 trillion, with US-denominated instruments growing 14% to about $22 trillion, due in part to an upswing in the use of swaps and swaptions to hedge mortgage pre-payment risk. Notionals in euro-denominated swaps grew 18% in dollar terms. But the BIS noted that the euro had appreciated 13% against the dollar during the same period. It was a similar situation for yen-denominated swaps, which grew 16% to $12 trillion – the yen strengthened 10% against the dollar during this period.

Increased currency volatility caused a surge in FX options business, which overall grew by 39% to $3.9 trillion in notionals outstanding. Contracts involving the euro swelled 66%, primarily driven by volatility of the euro/dollar currency pair in the second quarter. But forex derivatives as a whole only made a modest 8% increase to $18 trillion.

Meanwhile, equity-linked contracts returned to expansion with an 18% rise to $2.2 billion, as did commodity contracts which grew 39% to $777 million.

But evaluating the size of the market by notional outstandings is becoming increasingly outdated, said industry participants. They believe trading volumes would represent a better benchmark for OTC swaps activity. The BIS does produce such data, but only in its bi-annual reviews.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here